

1 **Clinical and Virologic Factors associated with Outcomes of COVID-19 before and after**
2 **Vaccination among Veterans: Retrospective Analysis from Six New England States**

3 Megan Lee, BS¹; Danielle Cosentino, BS²; Tassos C. Kyriakides, PhD³; Tricia Cavallaro, BS⁴;

4 Gary Stack, MD, PhD^{4,5}; Shaili Gupta, MBBS^{6,7}

5 ¹Yale School of Medicine, New Haven, CT

6 ²Department of Clinical Informatics, VA Connecticut Healthcare System, West Haven, CT

7 ³Department of Veterans' Affairs Cooperative Studies Program, VA Connecticut Healthcare
8 System, West Haven, CT

9 ⁴Pathology and Laboratory Medicine Service, VA Connecticut Healthcare System, West Haven,
10 CT

11 ⁵Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT

12 ⁶Department of Internal Medicine, Yale School of Medicine, New Haven, CT

13 ⁷Department of Medicine, VA Connecticut Healthcare System, West Haven, CT

14 **Corresponding Author:**

15 Shaili Gupta, MBBS

16 Department of Medicine, Yale School of Medicine; VA Connecticut Healthcare System

17 950 Campbell Ave, Bldg 1, 5th floor, Mailstop 111; West Haven, CT 06516

18 E-mail: shaili.gupta@yale.edu; phone: 203-932-5711, ext 4412; fax: 203-932-3748

19 **Word count:** 2,904 words

20 **Running Title:** COVID-19 in New England Veterans

21 **Conflicts of Interest:** The authors report no conflict of interest.

22 **Funding:** This work was supported by Center for Disease Control [BAA 75D301-20-R-68024 to
23 S.G.]

1 **Abstract:**

2
3 **Background:** A region-wide analysis of COVID-19 outcomes in New England has not been
4 done. We aimed to characterize clinical, demographic, and vaccination status affecting COVID-
5 19 clinical outcomes and describe viral epidemiology.

6
7 **Methods:** Clinical variables of Veterans with COVID-19 in Veterans Administration healthcare
8 systems in six New England states from April 8, 2020, to September 2, 2021 were correlated
9 with outcomes of 30-day mortality, non-psychiatric hospitalization, intensive care unit admission
10 (ICU-care), and post-vaccination infection. We sequenced 754 whole viral genomes and 197
11 partial genomes.

12
13 **Results:** Of 4,170 Veterans with COVID-19, 81% were White, 8% women, mean age was 60.1
14 \pm 17.7 years, and 2,399 became fully vaccinated. Overall, 19% Veterans needed hospitalization,
15 2.8% required ICU-care, and 3.7% died. Veterans with post-vaccination COVID-19 were older,
16 with higher rates of tobacco/drug use, CKD, and malignancy, and 0.38% died. Among the
17 unvaccinated, ICU-care and mortality correlated with age, while hospitalization correlated with
18 age, male sex, black race, drug use, chronic heart disease, COPD, CKD, and chronic liver
19 disease. Age, CKD, and alcohol use correlated with hospitalization in vaccinated patients.

20
21 Most New England Veterans (>97%) were infected with B.1 sub-lineages with the D614G
22 mutation in 2020 and early 2021. B.1.617.2 lineage (71%) predominated after July 2021,
23 including the post-vaccination infections.

24
25 **Conclusion:** In New England Veterans with mean age of 60 years, age and CKD significantly
26 correlated with hospitalization regardless of vaccination-status. Age correlated with mortality
27 and ICU-care among the unvaccinated. The Delta variant of SARS-CoV-2 (B.1.617.2)
28 dominated post-vaccination infections.

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

1 **Introduction**

2 The Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory
3 Syndrome Coronavirus-2 (SARS-CoV-2) has infected >40 million people in the United States
4 and caused over 650,000 deaths.¹ While some host and viral factors have been found to be
5 associated with transmission rates, disease severity, and mortality, there are significant variations
6 in these outcomes among specific populations.^{2,3} Some host-factors that have been shown to
7 have a significant association with clinical outcomes include age, Charlson comorbidity index
8 score, and body mass index (BMI).⁴⁻⁹ Viral factors have similarly been investigated for affecting
9 outcomes. U.S. Center for Disease Prevention (CDC) and World Health Organization (WHO)
10 have been diligently maintaining active surveillance of the evolving SARS-CoV-2 virus across
11 the globe, and several mutations have been known to result in the generation of Variants of
12 concern (VOC) and Variants of interest (VOI).^{10,11}

13 Early during the pandemic course in the United States, viral isolates on the East Coast of
14 the US were predominantly of the B.1 lineage that contained the Spike protein D614G
15 substitution.^{12,13} This substitution has been suggested to have enhanced transmissibility,¹⁴ said to
16 be supported by the higher upper airway viral loads and higher viral replication in lung epithelial
17 cells.¹⁵ With the increasing focus on emerging SARS-CoV-2 genetic variants, and concerns
18 about suboptimal protection from vaccines against infection by certain variants, more research is
19 required on how mutations affect risk of infection, as well as Veteran outcomes.¹⁶⁻²⁰ Both
20 regional epidemiology of the virus, and unique clinical characteristics of certain populations, can
21 play a role in determining outcomes of the infection.

22 The work presented here evaluated a unique regional population for factors associated
23 with clinical outcomes of COVID-19. U.S. Veterans make a reasonably vulnerable population

1 because of their average age of 58 years, which is higher than the average age of a U.S. resident
2 (38.5 years), and because Veterans are largely men (89%).²¹ Several studies have linked male
3 sex and higher age to poorer outcomes of COVID-19.^{2,22-24} In the beginning of the COVID-19
4 era, we conducted a small pilot study on Veterans with COVID-19 between April, 2020 and
5 September, 2020 from the same region of New England, and found age, dementia and low BMI
6 to be associated with mortality.²⁵ Here we present the analysis of outcomes throughout the
7 COVID-19 era in these Veterans from the New England states.

8 In a region-wide analysis of Veterans in New England, we aimed to (1) characterize
9 clinical, demographic, and viral factors affecting Veteran outcomes, (2) conduct genomic
10 evaluations of lineages and spike mutations throughout the COVID-19 era to determine
11 evolution of SARS-CoV-2, and (3) understand clinical and genomic factors that impact
12 morbidity and mortality risk in post-vaccination cases.

13

14 **Methods**

15 We conducted a retrospective analysis of demographic and clinical variables to identify
16 their relationship with outcomes of COVID-19 among Veterans in New England. The Veterans
17 Affairs Connecticut Healthcare System (VACHS) in West Haven, Connecticut has carried out
18 testing for SARS-CoV-2 on nasopharyngeal specimens from all six VA healthcare centers in
19 New England states (Connecticut, Massachusetts, Maine, New Hampshire, Rhode Island,
20 Vermont). The virus isolated from several samples testing positive was sent for whole genome
21 sequencing (WGS), and genomic data so generated provided insight into the evolution of the
22 virus in this large region. The VACHS Institutional Review Board (IRB) approved the creation

1 and maintenance of a data repository of all Veterans in New England diagnosed with COVID-19
2 and a viral repository of the SARS-CoV-2 RNA received from all six New England facilities.

3

4 *Cohort*

5 Our cohort included all Veterans receiving care at VA healthcare centers in six New
6 England states from April 8, 2020, to September 2, 2021, who had a diagnosis of COVID-19
7 based on one of three four PCR-based tests: Xpert® Xpress SARS-CoV-2 (GeneXpert system;
8 Cepheid), Simplexa® COVID-19 Direct Kit (LIAISON MDX; DiaSorin Molecular), BioFire®
9 Respiratory 2.1 Panel (BioFire FilmArray; BioFire Diagnostics), and Roche cobas® SARS-
10 CoV-2 test (cobas 6800 system; Roche Diagnostics), and had accessible chart records.

11

12 *Data Collection*

13 Data collection methods included utilizing Structured Query Language (SQL) to query
14 the VA Corporate Data Warehouse (CDW) for SARS-CoV-2 completed lab test results to
15 identify a Veteran cohort of confirmed SARS-CoV-2 cases. The specimens were all collected,
16 performed and resulted at a VA New England facility utilizing the electronic laboratory package
17 that is interfaced with the VA Computerized Patient Record System. Tests performed at VA
18 facilities outside of this area or other institutions were not included in the cohort. The dataset
19 included demographic variables [age, sex, race, body-mass index (BMI), and state of residence
20 when diagnosed with COVID-19] as recorded in Veteran medical records. Health information
21 was extracted for this cohort from the outpatient and inpatient datasets available. A unique
22 identifier for each Veteran allowed for the datasets to be joined and organized by each distinct
23 Veteran. This removed duplication of test results, health factors, admissions or pertinent

1 information across data sources. ICD-9 and ICD-10 diagnostic codes for the following
2 morbidities documented in the medical record were included: dementia, alcohol use, tobacco use,
3 drug use (cannabis, opioid, cocaine, hallucinogen, amphetamine, or anxiolytic), chronic heart
4 disease [including coronary artery disease (CAD), cardiomyopathy, atrial fibrillation, other
5 arrhythmia, congestive heart failure, and cerebrovascular accident], chronic lung disease
6 [including chronic obstructive pulmonary disease (COPD), asthma], chronic liver disease
7 (including cirrhotic and non-cirrhotic), chronic kidney disease (CKD), and diabetes mellitus.

8 The recorded primary outcomes were hospitalization, intensive care unit (ICU)
9 admission and 30-day all-cause mortality. Hospitalization was defined as within 2 days of a
10 positive COVID test. All admissions included were to a medical, surgical or ICU treating
11 specialty. Units and treating specialties coded specifically for rehabilitation or psychiatry were
12 excluded. Deaths were identified as occurring within the VA facility or the VA was provided a
13 death certificate, which was archived in the electronic Veteran registration package of VISTA.
14 Extracted data also treating specialty and number of admissions.

15 The secondary outcome was post-vaccination infection (i.e. acquiring COVID-19 after
16 being fully vaccinated), defined as first positive SARS-CoV-2 test two weeks after the second
17 dose of the Pfizer-BioNTech or Moderna vaccine or one dose of the Janssen vaccine (starting on
18 January 11, 2021).²⁶ Vaccination status was defined “fully vaccinated” if Veterans had either
19 received 2 doses of the Pfizer- BioNTech [BNT162b2 (Comirnaty)] or Moderna [mRNA-1273
20 (SpikeVAX)] vaccines, or one dose of the Janssen COVID-19 (Ad.26.COV2.S) vaccine.
21 Vaccination status was defined based on documentation of vaccine receipt at one of the New
22 England VHA sites or based on documented verification of vaccine receipt at a non-VA facility
23 in the VA electronic health record by a VA staff member.

1 The majority of data originated from entry into the VistA electronic record system. This
2 information is stored in the VA CDW, which requires use of SQL programming language.
3 Several data subsets were created as tables, joined, and pivoted in order to meet meaningful use
4 criteria. The application of SQL functions was used to accommodate the different reporting
5 methods across sites, BMI, length of stay, most recent laboratory values, and various numerical
6 results. Once all the data for this cohort was collated, it was analyzed and imported into
7 statistical software.

8

9 *Sample handling and Genomic Sequencing*

10 Handling of nasopharyngeal specimens and isolated virus was carried out by the VACHS
11 clinical laboratory as part of clinical care, following standardized CLIA guidelines. Specimens
12 were collected in viral transport medium, universal transport medium, or normal (0.9%) saline.
13 RNA was extracted from fresh or frozen specimens using either the KingFisher Flex system
14 (Thermo Fisher Scientific) or the QIAasymphony SP (QIAGEN), then shipped for whole genome
15 sequencing (WGS) to a non-VA reference laboratory. In some cases, variant determinations were
16 carried out on-site by multiplex PCR using the MassARRAY SARS-CoV-2 Variant Panel,
17 Version 3 (Agena Bioscience).

18 We evaluated viral genomes from 951 Veterans: WGS was conducted on 723 viral
19 genomes using Illumina (n = 224), Nanopore (n = 59), Illumina Nanoseq 6000 (n=358), and
20 Illumina COVIDSeq (n = 82); while the MassARRAY system alone was used for variant
21 determination on 228 Veteran specimens. Of the 951 total sequences, we had complete clinical
22 data for 859 individuals. In cases where the MassARRAY gave indeterminate results or when the
23 variant type was not included in the PCR panel, the specimens were reflexed to WGS. We

1 correlated outcomes to identified variants, spike mutations, and lineages in 3 time periods: early
2 (March – September 2020), middle (October 2020 – March 2021), and late (April 2021 – July
3 2021).

4

5 *Statistical Analysis*

6 Logistic correlation analysis was used to find correlates of hospitalization, mortality, ICU
7 admission, and post-vaccination infection. We stratified Veterans by vaccination status. We first
8 conducted a univariate analysis, then used variables from the univariate analysis with $P < 0.10$ to
9 use in a stepwise multivariate model with a forward selection level of 0.1 and backward selection
10 level of 0.15. Z-tests were done to compare differences in proportions between vaccinated and
11 unvaccinated hospitalizations. All analyses were performed using STATA v16 (College Station,
12 TX).

13

14 **Results**

15

16 *Veteran Characteristics*

17 Of 4,170 Veterans in six New England states with confirmed SARS-CoV-2 during the
18 study period, average age was 60.1 ± 17.7 years, with 8% female and 81.1% White (Table 1a).
19 An early cohort of 274 Veterans from our pilot study were included in this analysis to ensure the
20 completeness of our analysis.²⁵ The most common comorbidities were chronic heart disease
21 (31%), diabetes (27%), and chronic lung disease (23%). Of the 2,399 Veterans who became fully
22 vaccinated in our study, 53% received the Pfizer vaccine, 41% received Moderna, and 6%
23 received Janssen (Table 1b).

1

2 *Associations with outcomes before and after vaccination*

3 Of the 4,170 Veterans who tested positive for COVID-19, a total of 811 Veterans were
4 hospitalized (19%) (first hospitalization not fully vaccinated: n = 759, fully vaccinated: n = 52),
5 with 118 having ICU admissions (2.8%) (not fully vaccinated: n = 112, fully vaccinated: n = 6),
6 and 199 deaths (4.7%) (not fully vaccinated: n = 190, fully vaccinated: n = 9). Only 0.38%
7 (9/2,399) of fully vaccinated patients died.

8 On multivariate regression (Table 2a), significant correlates of hospitalization in Veterans
9 who first tested positive for SARS-CoV-2 before vaccination were age [odds ratio (OR): 1.05,
10 95% confidence interval (CI): 1.04, 1.06], male gender (OR: 1.63, 95% CI: 1.02, 2.61), black
11 race (OR: 1.60, 95% CI: 1.28, 2.16), BMI of 30-34.9 (OR: 0.74, 95% CI: 0.57, 0.97), chronic
12 heart disease (OR: 1.64, 95% CI: 1.33, 2.01), COPD (OR: 1.39, 95% CI: 1.11, 1.75), chronic
13 liver disease, 95% CI: OR: 1.43 (1.05, 1.94), and CKD (OR: 1.69, 95% CI: 1.24, 2.32).
14 Significant correlates of ICU admission were age (OR: 1.04, 95% CI: 1.02, 1.05), BMI 30 – 34.9
15 (OR: 0.29, 95% CI: 0.15, 0.55), BMI 24 – 24.9 (OR: 0.48, 95% CI: 0.24, 0.94) and tobacco use
16 (OR: 2.24, 95% CI: 1.41, 3.57). The only significant correlate of mortality was age (OR: 1.09,
17 95% CI: 1.07, 1.10).

18 Out of Veterans who first tested positive for SARS-CoV-2 after full vaccination (n =
19 220) (Table 2b), significant correlates of hospitalization on multivariate analysis were age (OR:
20 1.03, 95% CI: 1.00, 1.06), alcohol use (OR: 2.76, 95% CI: 1.06, 7.13), and CKD (OR: 3.26, 95%
21 CI: 1.43, 7.47).

22

23 *Relationship between vaccination and COVID hospitalization rates*

1 A total of 220 (5.3% of total Veterans with positive COVID-19 test) Veterans tested
2 positive for COVID-19 for the first time after being fully vaccinated, compared to the 3,950
3 Veterans (95%) who first tested positive when they were not vaccinated (difference of
4 proportions: 0.90, 95% CI: 0.88, 0.92) (Figure 1). Of the 220 breakthrough cases, 24% (52 out of
5 220 cases) were hospitalized after testing positive the first time after vaccination, in comparison
6 to the 19% of Veterans who tested positive for COVID-19 for the first time before vaccination
7 and were hospitalized (759 out of 3,950 cases) (difference of proportions: 0.05, 95% CI: -0.10,
8 0.01).

9 There was a median of 111 days [25th pctl: 52 days, 75th pctl: 157 days) from being
10 considered “fully vaccinated” (2 weeks after last dose) to the date of COVID-19 diagnosis. In
11 regards to partially vaccinated Veterans, two hundred Veterans (4.8%) first tested positive for
12 COVID after their first vaccination but before being fully vaccinated, with 53 Veterans
13 hospitalized.

14

15 *Associations with first time Sars-CoV-2 positive test after full vaccination*

16 Among the Veterans who first tested positive for COVID after being fully vaccinated (n
17 = 220), the average age was 68.0 ± 15.3 years, 6.4% were female (n = 14), and 86% were white
18 (n = 186), 127 received the Pfizer-BioNTech vaccine (58%, 10% of all Pfizer recipients), 83
19 received Moderna (38%, 8.5% of all Moderna recipients), and 10 received Janssen (4.5%, 6.8%
20 of Janssen recipients) vaccine. Only 0.38% (9/2,399) of fully vaccinated Veterans died.

21 On multivariate analysis, we found that Veterans who tested positive for COVID-19 after
22 being fully vaccinated (n = 220) (Supplemental Table 1), when compared to Veterans who were
23 not fully vaccinated, were significantly more likely to be older (OR: 1.02, 95% CI: 1.02, 1.04),

1 and had higher rates of tobacco use (OR: 1.50, 95% CI: 1.11, 2.03), drug use (OR: 1.79, 95% CI:
2 1.06, 3.02), CKD (OR: 1.59, 95% CI: 1.07, 2.35), and malignancy (OR: 1.78, 95% CI: 1.02,
3 3.11). No significant differences were found based on vaccine manufacturer.

4

5 *Viral Sequencing*

6 From the WGS data, we found that New England Veterans (>97%) were infected with
7 B.1 and its sub-lineages with the D614G mutation in the early (n = 282) and middle period (n =
8 349) of the study.²⁵ In the late period (n = 277), the delta (B.1.617.2, 71%) lineages
9 predominated (Supplemental Table 2). The most common and prominent lineages and
10 subsequent hospitalizations within those lineages are shown in Figure 2. In the late period,
11 Veterans who were infected after vaccination (n = 102) were more likely to have been infected
12 with the delta variant (OR: 2.56, 95% CI: 1.41, 4.65) over other variants, but there was no
13 difference in rates of being infected with the Delta variant over other variants based on vaccine
14 status (p = 0.20). The most common spike mutations were D614G (n = 900), L452R (n = 245),
15 T487K (n = 231), P231 (n = 231), and T19R (n = 230) (Supplemental Table 3).

16

17 **Discussion**

18 Our study found that in an older cohort of Veterans with a high comorbidity burden, age
19 significantly correlated with hospitalization, ICU admission, and mortality in unvaccinated
20 populations. Drug use, tobacco use, CKD, and malignancy were higher in Veterans who
21 contracted post-vaccination infection, irrespective of vaccination type. Among those who were
22 infected post vaccination, age, alcohol use, and CKD correlated with hospitalization. The most
23 common lineages in 2020 were B.1 and B.1.2, while B.1.617.2 dominated infections during the

1 summer and fall of 2021. Our study is unique in that it includes comprehensive data from all
2 Veterans in six New England states and additionally characterizes post-vaccination infection
3 covariates. Veterans in our study are unique in that they are an older cohort with high rates of
4 comorbid disease,^{21,27} and understanding clinical factors that impact outcomes in this population
5 should help clinicians determine risks for Veterans with similar demographics.

6 Our data showed that starting in the summer of 2021, the B.1.617.2 (delta) variant
7 dominated the New England Veteran infections. This lineage did not associate with worse
8 hospitalization, ICU admission, or mortality in our study, but more people who were infected
9 after vaccination in the late period were more likely to have this variant. Laboratory studies have
10 shown the vaccine to be effective against the delta variant, although perhaps less so than other
11 variants^{16,28}, and one clinical study from the United Kingdom noted modest differences in
12 vaccine effectiveness from the delta variant as composed to the alpha variant.²⁹ However, these
13 latter findings must be taken into context that as delta becomes the predominant variant,^{20,30}
14 vaccine-induced immunity (especially among patients vaccinated early in 2021) may be
15 waning.¹⁷ Thus, ongoing efforts to better understand the duration of vaccine effectiveness and to
16 define the need and timing for booster vaccinations are critical.³¹

17 Among fully vaccinated Veterans, 9% of fully vaccinated Veterans had breakthrough
18 cases of COVID-19. This mirrors an increase in breakthrough cases throughout the globe.^{18-20,32}
19 Our study showed a statistically significant higher risk of getting infected before vaccination, as
20 compared to after vaccination, and the overall COVID-19 related hospitalizations were lower
21 among the fully vaccinated. However, among those who did get COVID-19 after being fully
22 vaccinated, the hospitalization rate was not statistically different compared to those who had it
23 before vaccination. Given the data surrounding vaccine efficacy against COVID-19

1 hospitalization,^{33,34} this may indicate that the severity of disease may be higher with the newest
2 variants of COVID-19 or that we did not have sufficient power to detect a difference. We did not
3 detect a difference in breakthrough infection in our vaccine-recipient cohort rates by vaccine
4 manufacturer, in contrast to other studies.³⁵ Nevertheless, continued efforts to increase
5 vaccination rates and encourage social distancing and mask use indoors are critical to curb
6 infection spread.^{18,19}

7 The comorbidities correlating with worse outcomes in our study were similar to analyses
8 in some other populations of patients with COVID-19. Like other studies, we found that age was
9 a significant correlate of worse outcomes.^{4,7,36-39} Male sex, which associated hospitalization in
10 our study, is another widely cited predictor of worse prognosis,^{22,24} with one meta-analysis citing
11 a global odds ratio of 2.84 for intensive treatment unit admission and 1.39 for higher odds of
12 death.²⁴ Our data also showed an increased rate of hospitalization among unvaccinated infected
13 black participants, as has been shown in some previous studies, but this effect was lost in
14 vaccinated black patients.^{40,41} In our univariate analysis, we found that Veterans with dementia
15 had a higher risk of hospitalization and death, which has been replicated in other studies,^{37,42,43}
16 but this effect was lost on multivariable analysis. Thus, the increased risk of dementia for poor
17 clinical outcomes may be explained by age and comorbidities but nevertheless emphasizes the
18 importance of additional monitoring required when caring for a patient with dementia;
19 providers and caregivers must ensure this vulnerable population receives sufficient support
20 throughout the course of their illness. Age, CKD, malignancy, drug use, and alcohol use were
21 shown to be risk factors for getting infected among the vaccinated Veterans, with age, CKD and
22 alcohol use being correlated most to hospitalization in this population. An understanding of

1 clinical variables impacting risks among the vaccinated is critical to inform the vaccine-booster
2 prioritization guidelines, and triaging guidelines for healthcare systems.

3 Limitations of this work include that it is specific to Veterans, a largely older male
4 cohort, and results may not be generalizable to other populations. Evaluation of Veteran
5 population is critical, however, given that these sex and age limitations also are known
6 associations for COVID-19 infection. Our study spanned the course of the COVID-19 pandemic
7 since its beginning in our region, and although triage algorithms in our hospital system did not
8 significantly change over this time period, our study encompasses both pre- and post-vaccination
9 time periods. We therefore analyzed outcomes in fully vaccinated Veterans and compared to
10 those among unvaccinated. We were only able to record hospitalizations within the VA system
11 and did not have results if Veterans were seen at outside hospitals. Furthermore, we are limited
12 by the retrospective nature of our review, and analysis via ICD codes may have missed diagnoses
13 due to incorrect or inaccurate coding. We did not have data on patients who did not test positive
14 for COVID-19; future work would report COVID-19 positivity based on vaccine status/type.
15 Post-vaccine hospitalizations had a shorter time to accumulate, and future studies should assess
16 how time-based factors (including waves of the virus and likelihood of being hospitalized or
17 infected over time) as well as vaccine uptake over time affect outcomes. Our study's strengths
18 include its comprehensive inclusion of all Veterans in New England, large study size, and novel
19 analysis of correlates of post-vaccination infection.

20

21 **Conclusion**

22 We found that in this regional cohort of Veterans with average age of 60 years and
23 multiple comorbidities, age significantly correlated with hospitalization, ICU admission, and

1 mortality. Veterans who tested positive for COVID-19 after vaccination were more likely to be
2 older and had higher rates of tobacco use, drug use, CKD, and malignancy. This suggests that
3 these populations may especially benefit from a booster dose. Our study also revealed that
4 among fully vaccinated Veterans who become infected with COVID-19, age, alcohol use, and
5 CKD associated with hospitalizations. This identifies vaccinated patients who test positive for
6 COVID-19 most at risk for hospitalization and can inform triage algorithms. Hospitalization
7 rates were similar among vaccinated and unvaccinated veterans, and mortality among vaccinated
8 Veterans was rare. While the most common lineages in 2020 were B.1 and B.1.2, the delta
9 variant of SARS-CoV-2 (B.1.617.2) dominated infections during the summer and early fall of
10 2021, and Veterans who were infected after vaccination were more likely to have this variant.

1 **Acknowledgements:** The authors thank Irina Tikhonova (Yale Center for Genome Analysis)
2 and Nathan D. Grubaugh (Yale School of Public Health) for conduction and analysis of whole
3 genome sequencing for some of the samples in the study. The authors also thank Danielle Plank
4 (VA Connecticut Healthcare System) for extracting RNA for whole genome sequencing.

5 **Author Contributions:** ML and SG participated in the conception, design, data collection,
6 analysis and interpretation of results, and manuscript preparation. DR participated in the data
7 collection, analysis and interpretation of results, and manuscript preparation. TCK participated in
8 the analysis and interpretation of results and manuscript preparation. TC and GS participated in
9 the conduction, analysis and interpretation of whole genome sequencing and in manuscript
10 preparation.

11 **Conflicts of Interest:** The authors report no conflict of interest.

12 **Funding:** This work was supported by Center for Disease Control [BAA 75D301-20-R-68024 to
13 S.G.].

14

15

16

17

18

19

20

21

22

23

Literature Cited

- 1
- 2
- 3 1. U.S. Department of Health & Human Services. Published COVID Data Tracker. Accessed
- 4 Sept 13, 2021.
- 5 2. Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, et al. Predictors of COVID-
- 6 19 severity: A literature review. *Rev Med Virol.* 2021;31(1):1-10.
- 7 3. Garibaldi BT, Fiksel J, Muschelli J, Robinson ML, Rouhizadeh M, Perin J, et al. Patient
- 8 Trajectories Among Persons Hospitalized for COVID-19 : A Cohort Study. *Ann Intern*
- 9 *Med.* 2021;174(1):33-41.
- 10 4. Ioannou GN, Locke E, Green P, Berry K, O'Hare AM, Shah JA, et al. Risk Factors for
- 11 Hospitalization, Mechanical Ventilation, or Death Among 107131 US Veterans With
- 12 SARS-CoV-2 Infection. *JAMA Netw Open.* 2020;3(9):e2022310.
- 13 5. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute
- 14 Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019
- 15 Pneumonia in Wuhan, China. *JAMA Intern Med.* 2020;180(7):934-943.
- 16 6. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázquez A, González-Díaz
- 17 A, Márquez-Salinas A, et al. Predicting Mortality Due to SARS-CoV-2: A Mechanistic
- 18 Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico. *J Clin Endocrinol*
- 19 *Metab.* 2020;105(8).
- 20 7. Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID-19: A
- 21 systematic review and meta-analysis of clinical characteristics, risk factors, and
- 22 outcomes. *J Med Virol.* 2021;93(3):1449-1458.
- 23 8. Mason KE, Maudsley G, McHale P, Pennington A, Day J, Barr B. Age-Adjusted
- 24 Associations Between Comorbidity and Outcomes of COVID-19: A Review of the
- 25 Evidence From the Early Stages of the Pandemic. *Front Public Health.* 2021;9:584182.
- 26 9. Smati S, Tramunt B, Wargny M, Caussy C, Gaborit B, Vazier C, et al. Relationship
- 27 between obesity and severe COVID-19 outcomes in patients with type 2 diabetes:
- 28 Results from the CORONADO study. *Diabetes Obes Metab.* 2021;23(2):391-403.
- 29 10. SARS-CoV-2 Variant Classifications and Definitions. Center for Disease Control and
- 30 Prevention. Published 2021. Accessed Sept 13, 2021.
- 31 11. Tracking SARS-CoV-2 variants. World Health Organization. Published 2021. Accessed
- 32 Sept 13, 2021.
- 33 12. Brufsky A. Distinct viral clades of SARS-CoV-2: Implications for modeling of viral spread.
- 34 *Journal of Medical Virology.* 2020;92(9):1386-1390.
- 35 13. GISAID. Freunde von GISAID e.V. <https://www.gisaid.org/>. Accessed Sept 19, 2021.
- 36 14. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking
- 37 Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19
- 38 Virus. *Cell.* 2020;182(4):812-827.e819.
- 39 15. Lorenzo-Redondo R, Nam HH, Roberts SC, Simons LM, Jennings LJ, Qi C, et al. A clade of
- 40 SARS-CoV-2 viruses associated with lower viral loads in patient upper airways.
- 41 *EBioMedicine.* 2020;62.
- 42 16. Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. Reduced
- 43 neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. *Cell.*
- 44 2021;184(16):4220-4236.e4213.

- 1 17. Nanduri S, Pilishvili T, Derado G, Soe MM, Dollard P, Wu H, et al. Effectiveness of Pfizer-
2 BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing
3 Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2
4 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021. *MMWR*
5 *Morb Mortal Wkly Rep.* 2021;70(34):1163-1166.
- 6 18. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. Covid-19
7 Breakthrough Infections in Vaccinated Health Care Workers. *N Engl J Med.* 2021.
- 8 19. Brown CM, Vostok J, Johnson H, Burns M, Gharpure R, Sami S, et al. Outbreak of SARS-
9 CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with
10 Large Public Gatherings - Barnstable County, Massachusetts, July 2021. *MMWR Morb*
11 *Mortal Wkly Rep.* 2021;70(31):1059-1062.
- 12 20. Thangaraj JWV, Yadav P, Kumar CG, Shete A, Nyayanit DA, Rani DS, et al. Predominance
13 of delta variant among the COVID-19 vaccinated and unvaccinated individuals, India,
14 May 2021. *J Infect.* 2021:S0163-4453(0121)00387-X.
- 15 21. Profile of Veterans: 2017. In: National Center for Veterans Analysis and Statistics
16 UDoVA, ed.
17 https://www.va.gov/vetdata/docs/SpecialReports/Profile_of_Veterans_2017.pdf2019.
- 18 22. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender Differences in Patients With
19 COVID-19: Focus on Severity and Mortality. *Front Public Health.* 2020;8:152.
- 20 23. Liu D, Wang Y, Wang J, Liu J, Yue Y, Liu W, et al. Characteristics and Outcomes of a
21 Sample of Patients With COVID-19 Identified Through Social Media in Wuhan, China:
22 Observational Study. *J Med Internet Res.* 2020;22(8):e20108.
- 23 24. Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al.
24 Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU
25 admission. *Nat Commun.* 2020;11(1):6317.
- 26 25. Lee M, Sallah YH, Petrone ME, Ringer M, Cosentino D, Vogels CBF, et al. COVID-19
27 Outcomes and Genomic characterization of SARS-CoV-2 isolated from Veterans in New
28 England States. *medRxiv.* 2021:2021.2004.2027.21256222.
- 29 26. When You've Been Fully Vaccinated. Centers for Disease Control and Prevention.
30 <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated.html>. Published
31 2021. Accessed Sept 09, 2021.
- 32 27. Census Bureau Releases 2020 Demographic Analysis Estimates. United States Census
33 Bureau. [https://www.census.gov/newsroom/press-releases/2020/2020-demographic-](https://www.census.gov/newsroom/press-releases/2020/2020-demographic-analysis-estimates.html)
34 [analysis-estimates.html](https://www.census.gov/newsroom/press-releases/2020/2020-demographic-analysis-estimates.html). Published 2020. Accessed 2021, Sept 13.
- 35 28. Liu J, Liu Y, Xia H, Zou J, Weaver SC, Swanson KA, et al. BNT162b2-elicited neutralization
36 of B.1.617 and other SARS-CoV-2 variants. *Nature.* 2021;596(7871):273-275.
- 37 29. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al.
38 Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med.*
39 2021;385(7):585-594.
- 40 30. Herlihy R, Bamberg W, Burakoff A, Alden N, Severson R, Bush E, et al. Rapid Increase in
41 Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - Mesa County, Colorado, April-
42 June 2021. *MMWR Morb Mortal Wkly Rep.* 2021;70(32):1084-1087.

- 1 31. Barrett JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, Folegatti PM, Gilbride C, et al. Phase
2 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces
3 multifunctional antibody responses. *Nat Med*. 2021;27(2):279-288.
- 4 32. Cook C, Patel NJ, D'Silva KM, Hsu TY, Dilorio M, Prisco L, et al. Clinical characteristics and
5 outcomes of COVID-19 breakthrough infections among vaccinated patients with
6 systemic autoimmune rheumatic diseases. *Ann Rheum Dis*. 2021.
- 7 33. Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness
8 of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health
9 system in the USA: a retrospective cohort study. *The Lancet*. 2021;398(10309):1407-
10 1416.
- 11 34. Self WH TM, Rhoads JP, et al. Comparative Effectiveness of Moderna, Pfizer-BioNTech,
12 and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations
13 Among Adults Without Immunocompromising Conditions — United States, March–
14 August 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70:1337–1343.
- 15 35. Cohn Barbara A, Cirillo Piera M, Murphy Caitlin C, Krigbaum Nickilou Y, Wallace Arthur
16 W. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021.
17 *Science*. 0(0):eabm0620.
- 18 36. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of
19 2020-133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical
20 Characterisation Protocol: prospective observational cohort study. *BMJ*.
21 2020;369:m1985-m1985.
- 22 37. Giorgi Rossi P, Marino M, Formisano D, Venturelli F, Vicentini M, Grilli R, et al.
23 Characteristics and outcomes of a cohort of COVID-19 patients in the Province of Reggio
24 Emilia, Italy. *PLoS One*. 2020;15(8):e0238281-e0238281.
- 25 38. Kim L, Garg S, O'Halloran A, Whitaker M, Pham H, Anderson EJ, et al. Risk Factors for
26 Intensive Care Unit Admission and In-hospital Mortality among Hospitalized Adults
27 Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated
28 Hospitalization Surveillance Network (COVID-NET). *Clin Infect Dis*. 2020:ciaa1012.
- 29 39. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors
30 associated with COVID-19-related death using OpenSAFELY. *Nature*.
31 2020;584(7821):430-436.
- 32 40. Cardemil CV, Dahl R, Prill MM, Cates J, Brown S, Perea A, et al. COVID-19-Related
33 Hospitalization Rates and Severe Outcomes Among Veterans From 5 Veterans Affairs
34 Medical Centers: Hospital-Based Surveillance Study. *JMIR Public Health Surveill*.
35 2021;7(1):e24502-e24502.
- 36 41. Gold JAW, Wong KK, Szablewski CM, Patel PR, Rossow J, da Silva J, et al. Characteristics
37 and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 - Georgia, March
38 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(18):545-550.
- 39 42. Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities
40 associated with mortality in 31,461 adults with COVID-19 in the United States: A
41 federated electronic medical record analysis. *PLoS Med*. 2020;17(9):e1003321-
42 e1003321.

- 1 43. Miyashita S, Yamada T, Mikami T, Miyashita H, Chopra N, Rizk D. Impact of dementia on
2 clinical outcomes in elderly patients with coronavirus 2019 (COVID-19): an experience in
3 New York. *Geriatr Gerontol Int*. 2020;20(7):732-734.
4

Table 1a. Patient characteristics (n = 4,170)

Demographics		Comorbidities	
Age (years)	60.1 ±17.7	Dementia	86 (12.06)
Sex		Alcohol use	286 (6.86)
Male	3,835 (92.0)	Tobacco use	753 (18.1)
Female	335 (8.03)	Drug use	177 (4.24)
Race		Cannabis	56 (1.34)
White	3,320 (81.1)	Opioid	25 (0.60)
Black	526 (12.9)	Cocaine	49 (1.18)
American Indian or Alaskan	28 (0.68)	Other drugs	102 (2.45)
Native Hawaiian/Pacific Islander	15 (0.37)	Chronic Heart Disease	1,289 (30.9)
Asian	45 (1.10)	CAD	633 (15.2)
Unknown/Declined	159 (3.88)	Cardiomyopathy	136 (3.26)
Ethnicity		Afib	552 (13.2)
Non-Hispanic	3,635 (88.8)	Other arrhythmia	427 (10.2)
Hispanic	272 (6.64)	CHF	410 (9.83)
Unknown/Declined	178 (4.61)	CVA	137 (3.29)
State		Chronic Lung disease	946 (22.7)
Massachusetts	1,182 (43.7)	COPD	701 (16.8)
Connecticut	1,205 (28.9)	Asthma	370 (8.87)
Maine	258 (6.19)	Chronic liver disease	350 (8.39)
New Hampshire	377 (9.04)	Cirrhosis	93 (2.23)
Rhode Island	506 (12.1)	Non-cirrhotic	312 (7.48)
Vermont	2 (0.05)	CKD	277 (6.64)
BMI category		Malignancy	111 (2.66)
<25	467 (14.5)	Diabetes	1,141 (27.4)
25-30	1,041 (32.4)		
30-35	965 (30.0)		
>35	739 (14.5)		

Table 1b. Vaccine Manufacturer among vaccinated patients (n = 2,399)

Vaccine Manufacturer	
Pfizer-BioNTech	1,270 (52.9)
Moderna	982 (40.9)
Janssen	147 (6.1)

Results presented as n (%). Abbreviations: Afib: atrial fibrillation, CAD: coronary artery disease, CHF: congestive heart failure, CKD: chronic kidney disease, COPD: chronic obstructive pulmonary disease, CVA: cerebrovascular accident

Table 2a. Regression analysis of correlates of hospitalization, ICU admission, and death in unvaccinated patients (n = 3,950)

	Hospitalization		ICU admission		Death	
	Univariate	Multivariate	Univariate	Multivariate	Univariate	Multivariate
Age	1.05 (1.06, 1.07)*	1.05 (1.04, 1.06)*	1.04 (1.03, 1.05)*	1.04 (1.02, 1.06)*	1.10 (1.09, 1.12)*	1.09 (1.07, 1.10)*
Male sex	3.00 (1.98, 4.55)*	1.66 (1.04, 2.65)*	2.43 (0.89, 6.63)*		3.47 (1.41, 8.50)*	
Race						
White	Ref	Ref	Ref		Ref	
Black	1.22 (0.97, 1.53)*	1.60 (1.22, 2.08)*	0.64 (0.33, 1.25)		0.49 (0.28, 0.84)*	
Other	0.67 (0.46, 0.98)*	1.37 (0.88, 2.16)	0.82 (0.35, 1.89)		0.37 (0.15, 0.90)*	
BMI						
>35	Ref	Ref	Ref	Ref	Ref	
30 - 34.9	0.90 (0.71, 1.15)	0.75 (0.57, 0.97)*	0.36 (0.19, 0.68)*	0.29 (0.15, 0.55)*	0.96 (0.55, 1.67)	0.69 (0.39, 1.22)
25 - 29.9	1.18 (0.94, 1.50)	0.93 (0.72, 1.23)	0.95 (0.58, 1.56)	0.73 (0.44, 1.21)	1.31 (0.78, 2.20)	0.69 (0.40, 1.20)
<25	1.68 (1.28, 2.21)*	1.13 (0.83, 1.53)	0.76 (0.40, 1.45)	0.48 (0.24, 0.94)*	3.26 (1.94, 5.50)*	1.42 (0.81, 2.51)
Dementia	2.69 (1.70, 4.28)*	1.65 (0.91, 2.98)	1.38 (0.42, 4.44)		5.82 (3.33, 10.2)*	1.47 (0.65, 3.37)
Diabetes	2.76 (1.93, 2.69)*	1.11 (0.91, 1.41)	1.80 (1.23, 2.65)*		1.47 (1.09, 2.00)*	
Alcohol	1.54 (1.16, 2.06)*	1.38 (0.98, 1.96)	1.88 (1.04, 3.41)*	1.76 (0.92, 3.35)	0.51 (0.24, 1.10)	
Tobacco	1.31 (1.07, 1.59)*		2.16 (1.43, 3.25)*	2.24 (1.41, 3.57)*	1.10 (0.76, 1.58)	
Drug use	1.35 (1.12, 1.63)*	1.68 (1.10, 2.57)*	2.01 (1.34, 3.01)*		1.00 (0.70, 1.45)	
Chronic heart disease	4.10 (3.38, 4.83)*	1.67 (1.36, 2.05)*	2.86 (1.96, 4.17)*		2.89 (2.16, 3.87)*	
COPD	2.79 (2.32, 3.36)*	1.44 (1.16, 1.80)*	2.47 (1.65, 3.71)*		2.03 (1.47, 2.82)*	
Asthma	1.00 (0.76, 1.32)		1.02 (0.52, 1.96)		0.43 (0.21, 0.88)*	
Chronic liver	1.40 (1.07, 1.82)*	1.47 (1.08, 2.00)*	1.47 (0.81, 2.65)		0.92 (0.54, 1.58)	
CKD	3.91 (3.00, 5.10)*	1.75 (1.28, 2.57)*	3.04 (1.80, 5.13)*		2.62 (1.71, 4.03)*	
Malignancy	2.54 (1.69, 3.85)*		2.25 (0.97, 5.26)*		2.21 (1.13, 4.32)*	


Table 2b. Regression analysis of correlates of hospitalization in patients who first became COVID+ after full vaccination (n = 220)

	Hospitalization	
	Univariate	Multivariate
Age	1.03 (1.01, 1.05)*	1.03 (1.00, 1.06)*
Male sex	4.28 (0.55, 33.50)	
Race		
White	Ref	
Black	0.92 (0.32, 2.63)	
Other	0.89 (0.18, 4.46)	
BMI		
>35	Ref	
30 - 34.9	0.78 (0.30, 2.00)	
25 - 29.9	0.77 (0.31, 1.90)	
<25	1.56 (1.57, 4.31)	
Dementia	1.08 (0.211, 5.52)	
Diabetes	1.89 (1.01, 3.56)*	
Alcohol	2.30 (0.93, 5.68)*	2.76 (1.06, 7.13)*
Tobacco	0.86 (0.40, 1.83)	
Drug use	1.04 (0.51, 2.10)	
Chronic heart disease	2.11 (1.12, 3.96)*	1.35 (0.67, 2.75)
COPD	1.27 (0.61, 2.67)	
Asthma	0.94 (0.33, 2.69)	
Chronic liver	0.95 (0.33, 2.70)	
CKD	3.60 (1.65, 7.87)*	3.26 (1.43, 7.47)*
Malignancy	1.91 (0.54, 6.82)	

Results presented as odds ratio (95% confidence interval).

Abbreviations: BMI: body mass index, CKD: chronic kidney disease, COPD: chronic obstructive pulmonary disease

Figure 1. Hospitalization status by COVID vaccination status



^aDifference of proportions: 0.90 (95% CI: 0.88, 0.92)

^bDifference of proportions: 0.05 (95% CI: -0.10, 0.013)

Figure 2. Graph of lineages and hospitalizations within lineages by time

Figure 2a. Prominent lineages by time (n = 572)




Figure 2b. Hospitalizations within prominent lineages by time (n = 56)

